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Background: The aim was to ascertain the 1-year clinical outcomes of 1,234 patients who underwent implantations
of sirolimus-eluting stents (SES) for acute myocardial infarction (MI) in the multinational e-SELECT registry.
Methods: Fifteen thousand and one hundred and forty-seven patients treated with SES were entered in the
e-SELECT registry, of whom 1,234 presented within <24 hours of onset of acute MI.
Results: At 1 year, the rates of major adverse cardiac events (MACE) (5.5% vs. 4.8%; P = 0.28) were similarly
low in the acute and no acute MI groups. The rates of definite/probable stent thrombosis (ST) were higher in
the acute MI group (2.1%vs; 0.88%, P < 0.001). ST was a strong independent predictor of death at 1 year
(HR 13.4; 95% CI 5.0, 36.0; P < 0.001) and MI (HR 58.9; 95% CI 26.9, 129.1; P < 0.001). Dual antiplatelet
therapy (DAPT) compliance at 6 months was 96.0% in the acute MI versus 94.5% in the no acute MI group
(P = 0.03).
Conclusion: In selected patients presenting within <24 hours of acute MI onset and highly compliant with DAPT,
SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared to no acute
MI patients.
Condensed abstract
In the e-SELECT registry which included 15,147 patients treated with sirolimus-eluting stent (SES), we ascertained
the 1-year clinical outcomes of 1,234 patients who presented within <24 hours of acute MI onset. In acute MI
patients SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared
to no acute MI patients (MACE: 5.5% vs. 4.8%; P = 0.28; ST: 2.1 vs. 0.88%, P < 0.001). (J Interven Cardiol
2012;25:253–261)
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Introduction
Early percutaneous coronary intervention (PCI) with
stent implantation is a widely accepted strategy for
the management of acute myocardial infarction (MI)
with or without ST segment elevation.1,2 Furthermore,
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in comparative trials, sirolimus-eluting stents (SES)
were distinctly more effective than bare metal stents
(BMS) in the prevention of coronary artery resteno-
sis after primary PCI,3–5 whereas the performance of
paclitaxel-eluting stents has been mixed.6,7 In con-
trast with their reliable estimates of angiographic end-
points, such as target lesion and target vessel resteno-
sis, randomized trials have been weak at measuring
clinical outcomes, because of their stringent inclusion
and exclusion criteria, and the low incidence of adverse
events observed in selected, relatively low-risk popula-
tions treated by highly experienced interventional car-
diologists. Large, meticulously organized multicenter
registries are a powerful means of studying the per-
formance of new therapies broadly implemented in
“real-world” practice, and of examining the incidence
of infrequent, long-term clinical events, such as stent
thrombosis (ST).
Using data from e-SELECT, a prospective observa-
tional registry of patients who underwent implantation
of SES, we focused on the 1-year clinical outcomes
of patients who underwent PCI within <24 hours af-
ter the onset of stent thrombosis-elevation myocardial
infarction (STEMI) or non-STEMI.
Registry Sample and Methods
The e-SELECT worldwide registry has been de-
scribed elsewhere in detail.8 In brief, baseline data were
collected between May 2006 and April 2008 in consec-
utive recipients of ≥1 CYPHER Select R© or CYPHER
Select R© Plus (Cordis Corporation, Bridgewater, NJ,
USA), implanted at 320 medical centers in 56 coun-
tries. The protocol specified few inclusion or exclu-
sion criteria. Off-label indications were not prohibited,
and all post-procedural medical management, includ-
ing antithrombotic therapy, was prescribed according
to usual local practices. The patients were followed
clinically at 30, 180, and 360 days after SES implanta-
tion. The protocol was approved by the ethics commit-
tee of each participating medical center and the patients
granted their consent to participate in the registry after
undergoing the index procedure.
Study Groups Definitions. This analysis com-
pares the clinical, angiographic and procedural char-
acteristics, and 1-year clinical outcomes of 1,234 pa-
tients who presented within <24 hours of the onset of
MI (acute MI group) versus 13,913 patients who un-
derwent SES implants for indications other than acute
MI (no acute MI group). MI was classified accord-
ing to ST changes on the surface electrocardiogram
(ECG) as non-STEMI or STEMI, and was diagnosed
on the basis of elevated serum creatine kinase (CK) or
CK-MB enzyme concentrations, in presence (Q-wave
MI) or absence (non Q-wave MI) of new patholog-
ical Q waves in ≥2 contiguous leads of the surface
ECG. MI was classified as undetermined if the pre-
and postprocedural ECG was not available. Among the
1,234 patients who presented within <24 hours of MI
onset, 589 (47.7%) presented within <12 hours.
Data Collection and Management. The data col-
lected by the e-SELECT registry include demographic
information, general health and cardiovascular history,
assessment of angina status, co-morbidity,9 lesion and
procedure characteristics, procedural outcomes, mea-
surements of serum cardiac enzymes and creatinine,
pre- and postprocedural ECG, cardiac medications and
antithrombotic regimens, and postprocedural clinical
observations up to 1 year of follow-up.
The data were collected electronically at each
participating medical center, transferred to an in-
dependent data management organization (KIKA
Medical, Nancy, France), and analyzed by an inde-
pendent clinical research organization (Cardialysis,
Rotterdam, Netherlands). The overall consistency and
accuracy of data collection was monitored by an inde-
pendent organization (Covance, Princeton, NJ, USA)
in a random selection of 20% of the overall sample at
100 enrolling centers.
End-points of the e-SELECT Registry. The pri-
mary end-point of the registry was a composite of def-
inite and probable ST, as defined by the Academic
Research Consortium (ARC)10 at 1 year of follow-up.
The secondary end-points at 1 year included MB ac-
cording to the Safety and Efficacy of Enoxaparin in PCI
(STEEPLE) trial definition,11 cardiac and noncardiac
deaths, MI, and major adverse cardiac events (MACE),
defined as any death, MI, or target lesion revascular-
ization (TLR).
Study Organization and Supervision. A steering
committee (Appendix A) planned the analysis of the
registry, and presentations and publications of the re-
sults. A clinical event committee (Appendix A), com-
posed of interventional cardiologists not associated
with the sponsor and not participants in the registry,
adjudicated all MACE, MB and acute, subacute, and
late ST by a systematic review of the data collection
forms and by review of the source documents, ECG,
and angiograms, when necessary.
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Statistical Analysis. For all patients, standard de-
scriptive statistics were used for baseline, lesion, and
procedural characteristics and for clinical results. Con-
tinuous variables are presented as means ± standard
deviation (SD), or median and range, and categori-
cal variables are presented as counts and percentages.
Cumulative rates of adverse clinical events were calcu-
lated with event-specific adjusted denominators, such
that all patients experiencing an adverse event within
360 days or followed for ≥330 days after the index
procedure contribute to the denominator. Comparisons
of continuous variables between both groups were
made using one-way analysis of variance. Fisher’s ex-
act test was used to compare dichotomous variables
and cumulative event rates. Because the cumulative
rates of adverse clinical events did not correct for
censoring within 330 days after the index procedure,
Kaplan-Meier curves and time-to-event summaries
were constructed, and the life-table method was used to
examine the long-term incidence of clinical and safety
end-points, correcting for all censoring, though the re-
sults were similar. Predictors of major clinical safety
end-points were identified with the Cox proportional
hazards, single and multiple variable analyses. For each
outcome end-point, baseline covariates identified by
the single variable analysis (P < 0.005) by a non-
significant proportional hazards assumption test (P >
0.05 combined with graphic assessment), and by clin-
ical relevance, were included in the multiple variable
model stepwise selection procedure. An entry criterion
probability value of 0.10 and a stay criterion of 0.15
were used, and baseline covariates with >15% miss-
ing values were excluded from the analysis. Missing
values were not imputed. P values <0.05 were con-
sidered statistically significant. All statistical analyses
were performed with the SAS software, version 8.2
(SAS Institute, Cary, NC, USA).
Results
Registry Sample and Clinical Characteristics of
the Study Subgroups. The e-SELECT sample com-
prised 15,147 patients who fulfilled the inclusion and
exclusion criteria specified in the protocol. Follow-
up data were available in 14,905 patients at 30 days,
14,430 at 6 months, and 13,693 at 1 year, representing
99%, 96%, and 92% of survivors, respectively. This
subgroup analysis compares the baseline clinical and
angiographic characteristics, and the procedural and
1-year clinical outcomes of 1,234 patients (8.1%) with
1,507 treated lesions, who presented within 24 hours
of onset of acute MI (acute MI group), versus those of
13,913 patients (91.8%) with 18,481 lesions, who un-
derwent SES for other indications (no acute MI group).
The clinical characteristics of the 2 groups are shown
in Table 1. The prevalence of (a) prior percutaneous or
surgical revascularization, (b) risk factors for coronary
artery disease (except for smoking), and (c) renal insuf-
ficiency was significantly higher in the no acute MI than
in the acute MI group. Patients in the no acute MI group
were also significantly more likely to present with mul-
tiple vessel disease.
Subgroups and Index Procedural and Angio-
graphic Characteristics. The lesion and procedu-
ral characteristics of the patient subgroups are shown
in Table 2. The mean reference vessel diameter was
significantly smaller, and mean preprocedural percent
vessel stenosis significantly greater in the acute MI
than in the no acute MI group. However, the proportion
of restenotic lesions and the overall lesion complexity
were significantly greater in the no acute MI group.
Accordingly, the mean numbers of lesions and vessels
treated, and the mean number of stents implanted per
patient were greater in the no acute MI than in the
acute MI group (Table 2). Finally, approximately 60%
and one-third of patients were treated with aspirin and
clopidogrel, respectively, before undergoing the index
SES implant procedure in the MI group, versus nearly
90% and one-third of patients, respectively, in the no
acute MI group (P < 0.001 for both comparisons).
Long-Term Antithrombotic Therapy. The com-
pliance with dual antiplatelet therapy (DAPT) was high
in both patient subgroups (Table 3). At 30-day follow-
up, 98.0% and 98.1% of patients in the acute MI and
no acute MI groups, respectively, were treated with as-
pirin and clopidogrel or ticlopidine, while 81.7% and
79.2% of patients, respectively, remained on DAPT at
12 months.
Stent Thrombosis, Major Bleeding, and Other
Major Adverse Clinical Events. The rates of ST,
MB, and MACE at 1 year are presented in Table 4.
The 1-year rates of ST were significantly higher in
the acute MI than in the no acute MI group, due to
a significantly higher incidence of acute and subacute
ST. In the first 30 days, the rate of MB was 0.74% in
the acute MI versus 0.35% in the no acute MI group (P
= 0.47). Between 31 and 180 days, the rate of MB was
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Table 1. Baseline Characteristics of Patients Presenting within 24 h of Onset of Acute MI (Acute MI), versus the Remainder (No Acute MI) of
the e-SELECT Registry Sample
Acute MI (n = 1,234) No Acute MI (n = 13,913) P Value
Age, y 60.3 ± 11.8 62.3 ± 10.7 <0.001
Men 77.7 (959/1,234) 75.2 (10,464/13,913)) 0.053
Body mass index ≥30 20.5 (253/1,232) 24.7 (3,420/13,829) <0.001
History of:
Earlier myocardial infarction 34.8 (429/1,234) 32.0 (4425/13,849) <0.045
PCI 13.8 (170/1,234) 33.8 (4,680/13,849) <0.001
Coronary artery bypass graft surgery 4.9 (60/1,234) 9.5 (1,310/13,849) <0.001
Diabetes 28.2 (348/1,234) 30.5 (4,229/13,849) 0.09
Insulin-dependent diabetes 21.3 (74/348) 27.5 (1,164/4,229) 0.012
Hypertension 55.4 (684/1,234) 68.5 (9,487/13,849) <0.001
Hyperlipidemia 56.1 (692/1,234) 69.3 (9,597/13,849) <0.001
Current and past smoking 59.9 (739/1,234) 52.9 (7,321/13,849) <0.001
Peripheral vascular disease 4.0 (49/1.234) 6.4 (892/13,849) <0.001
Cerebral vascular disease 3.6 (44/1,234) 4.3 (599/13,849) 0.24
Serum creatinine >2.0 mg/dL 1.7 (19/1,101) 2.7 (332/12,306) 0.06
Chronic lung disease 3.9 (48/1,234) 4.0 (549/13,849) 1.00
Mean Charlson index score 1.0 ± 1.2 1.1 ± 1.3 0.018
Charlson index score ≥3 8.7 (107/1,234) 10.4 (1,439/13,849) 0.056
Coronary arteries with >50%stenoses
0 8.6 (106/1,234) 8.6 (1,201/13,913) 1.00
1 82.7 (1,021/1,234) 76.6 (10,646/13,913) <0.001
2 7.9 (97/1,234) 13.5 (1,878/13,913) <0.001
3 0.7 (9/1,234) 1.3 (184/13,913) 0.08
Target vessel
Left main coronary artery 1.7 (25/1,477) 2.3 (424/18,087) 0.12
Left anterior descending artery 53.7 (793/1,477) 50.8 (9,188/18,087) 0.035
Circumflex artery 18.8 (278/1,477) 22.2 (4,013/18,087) 0.003
Right coronary artery 26.8 (396/1,477) 25.9 (4,680/18,087) 0.44
Bypass graft 1.6 (24/1,501) 1.9 (347/18,434) 0.49
Values are means ± SD, or % (numbers) of observations.
significantly higher in the acute MI than in the no acute
MI group (0.46% vs. 0.24%, P = 0.04). Between 181
and 360 days the rates of MB were similar in both
groups (0.20% vs. 0.27%, P = 0.1). At 1 year, the rates
of deaths from all causes, cardiac deaths, MI, TLR,
and MB were similarly low in both groups (Table 4).
Figure 1 illustrates the significant difference between
the 2 study groups in cumulative rates of definite and
probable ST within the first month of follow-up and
low incidence of ST in both groups thereafter.
Predictors of Adverse Clinical Events. The in-
dependent predictors of death, MI, ST, and MB in the
acute MI group by multiple variable analysis are shown
in Table 5. ARC-defined definite or probable ST re-
lated to the index procedure was a strong independent
predictor of death and recurrent MI. Total or partial
temporary interruption of DAPT within 30 days after
the index procedure was a strong independent predictor
of ST.
Discussion
In this subgroup analysis of the e-SELECT registry,
the rates of death, MI, and TLR among patients pre-
senting within <24 hours of acute MI onset were low.
The incidence of acute and subacute ST in the acute
MI group was higher than in the no acute MI group.
Discontinuation of DAPT before 30 days was an in-
dependent predictor of ST. Interestingly, the increased
rate of ST in the acute MI group was driven by a higher
incidence of early (0 to 30 days) thrombotic events.
Several randomized trials and meta-analyses have
compared the use of DES and BMS in the setting
of primary PCI for acute MI. A lower rate of repeat
revascularization was regularly observed with DES,
without increase in the rates of death, recurrent MI
or ST at 1 year.12 Long-term follow-up was reported
in 3 studies.13–15 No difference in the rate of late ST
was observed between DES and BMS, although these
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Table 2. Lesion and Procedure Characteristics in 1,234 Patients Presenting within 24 h of Onset of Acute MI (Acute MI), versus the
Remainder (No Acute MI) of the e-SELECT Registry Sample
Acute MI No Acute MI
(n = 1,234 patients, (n = 13,913 patients,
1,507 lesions, 1,769 stents) 18,481 lesions, 21,723 stents) P Value∗
Reference vessel diameter, mm∗ 2.8 ± 0.45 2.92 ± 0.45 <0.013
Preprocedural percent stenosis 89.9 ± 13.7 84.1 ± 12.1 <0.001
Lesion length, mm∗ 20.02 ± 10.72 20.25 ± 11.65 0.45
Target lesion types
Restenotic† 6.1 (90/1,486) 12.2 (2,224/18,165) 0.001
In-stent restenosis† 5.2 (78/1,486) 11.6 (2,103/18,165) 0.005
Length ≥30 mm†† 11.3 (139/1,225) 13.7 (1,874/13,710) 0.023
Reference vessel diameter <2.25 mm†† 6.4 (79/1,226) 3.7 (506/13,721) <0.001
Ostial† 11.2 (166/1,486) 12.7 (2,310/18,165) 0.09
Moderately or severely calcified† 18.0 (245/1,362) 24.2 (2,766/16,418) <0.001
Procedural characteristics
Numbers per patient
Vessels treated 1.1 ± 0.35 1.18 ± 0.43 <0.001
Lesions treated 1.2 ± 0.51 1.33 ± 0.62 <0.001
Stents implanted 1.4 ± 0.73 1.56 ± 0.88 <0.001
Overlapping stents†† 13.2 (164/1,234) 14.8 (2,054/13,913) 0.002
Total stent length, mm
Per lesion 25.8 ± 11.90 25.32 ± 13.29 0.18
Per patient 31.5 ± 16.95 33.65 ± 21.28 0.001
Direct stenting 33.6 (500/1,486) 35.8 (6,512/18,165) 0.09
Postdilatation 33.0 (546/1,654) 36.3 (7,510/20,671) <0.007
Maximum pressure per stent, atm 15.6 ± 3.1 15.5 ± 3.3 0.25
Intravascular ultrasound imaging 1.8 (26/1,447) 3.8 (687/17,847) <0.001
Preprocedural antithrombotic regimens
Aspirin 59.7 (717/1,201) 88.1 (12,006/13,630) <0.001
Clopidogrel 36.7 (441/1,201) 62.5 (8,516/13,623) <0.001
Ticlopidine 0.3 (4/1,198) 2.0 (277/13,591) <0.001
Values are means ± SD, or % (numbers) of observations. ∗Visual estimate; †calculated per lesion; ††calculated per patient.
studies were underpowered to assess this safety end-
point. Registries have generated conflicting data. In
a large US state-based registry, Mauri et al. noted a
significant difference in the rate of repeat revascu-
larization and a decrease in all-cause mortality fa-
voring DES.16 In contrast, Steg et al. reported a
higher rate of death at 2 years in patients presenting
with acute MI who received a DES during the initial
hospitalization.17
The reported incidence of late ST after DES im-
plantation varies between 0.2 and 0.6% per year.18–20
Pathological studies have shown that lack of complete
endothelialization may be a leading cause of late DES
thrombosis.21,22 Furthermore Nakazawa et al. observed
considerably less vascular healing at plaque ruptures of
culprit lesions than in stable culprit lesions.23 Screen-
ing acute MI patients undergoing primary PCI for po-
tential contraindications to prolonged DAPT may be
difficult. In the PREMIER registry, nearly 1 in 7 pa-
tients who received a DES during primary PCI were
no longer treated with a thienopyridine 30 days af-
ter the procedure. Prematurely stopping thienopyri-
dine therapy was strongly associated with subsequent
mortality.24
Our subgroup analysis confirmed a high compliance
with DAPT, similar to that observed among the sta-
ble patients enrolled in the e-SELECT registry. More-
over, the issues regarding the prescription of prolonged
DAPT after implantation of a DES during primary PCI
are overshadowed by the benefits it confers to patients
presenting with an acute coronary syndrome (ACS).
Given these demonstrated benefits, current guidelines
on the management of STEMI recommend DAPT for
1 year after primary PCI, regardless of the type of stent
implanted.1,25 Therefore, in acute MI treated by pri-
mary PCI, patient education should emphasize the im-
portance of complying with long-term DAPT, whether
or not a DES has been implanted. Careful patient
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Table 3. Antithrombotic Regimens up to 360 Days of Follow-Up in Each Study Group
Acute MI No Acute MI
Regimen (n = 1,234 Patients) (n = 13,913 Patients) P Value
Discharge
Aspirin 99.6 (1,226/1231) 98.6 (13,597/13,782) 0.003
Clopidogrel 99.5 (1,225/1231) 98.5 (13,588/13,788) 0.003
Ticlopidine 0.5 (6/1225) 1.4 (188/13,645) 0.005
DAPT 99.4 (1,218/1225) 98.5 (13,430/13,624) 0.009
1 month
Aspirin 99.0 (1,146/1,158) 98.4 (12,997/13,207) 0.17
Clopidogrel 99.0 (1,147/1,158) 98.0 (12,948/13,207) 0.013
Ticlopidine 0.9 (11/1,158) 1.7 (221/13,207) 0.07
Dual antiplatelet therapy 98.1 (1,136/1,158) 98.0 (12,940/13,207) 0.91
6 months
Aspirin 98.2 (1,070/1,090) 97.4 (12.387/12,719) 0.13
Clopidogrel 97.2 (1,060/1,090) 95.2 (12,107/12,719) 0.001
Ticlopidine 0.5 (5/1,090) 1.5 (186/12,719) 0.004
Dual antiplatelet therapy 96.0 (1,047/1,090) 94.5 (12,022/12,719) 0.030
1 year
Aspirin 97.0 (1,080/1,113) 95.9 (11,907/12,420) 0.07
Clopidogrel 83.1 (925/1,113) 80.9 (10,052/12,420) 0.08
Ticlopidine 0.4 (4/1,113) 1.3 (161/12,420) 0.004
Dual antiplatelet therapy 81.7 (909/1,113) 79.2 (9,835/12,420) 0.053
Values are % (numbers) of observations; different denominators are due to missing data and deaths during follow-up.
Table 4. Cumulative Rates of Adverse Clinical Events at 1 Year of Follow-Up in Each Study Group
Acute MI No Acute MI
(n = 1,234) (n = 13,913) P Value
Definite or probable stent thrombosis 2.12 (24/1,131) 0.88 (111/12,618) <0.001
Acute (0–1 day) 0.24 (3/1,233) 0.05 (7/13,849) 0.042
Subacute (2–30 days) 1.32 (16/1,215) 0.44 (61/13,724) <0.001
Early (0–30 days) 1.56 (19/1,215) 0.49 (68/13,724) <0.001
Late (31–360 days) 0.44 (5/1,125) 0.34 (43/12,579) 0.59
Any ARC stent thrombosis 2.72 (31/1,137) 1.26 (160/12,661) <0.001
Definite 1.56 (18/1,127) 0.55 (70/12,588) <0.001
Probable 0.53 (6/1,129) 0.32 (41/12,598) 0.28
Possible 0.71 (8/1,132) 0.39 (50/12,612) 0.14
Death 2.18 (25/1,147) 1.65 (211/12,764) 0.19
Myocardial infarction 2.57 (29/1,127) 1.86 (235/12,612) 0.11
TLR 2.13 (24/1,127) 2.14 (269/12,601) 1.00
Major adverse cardiac events 5.48 (63/1,149) 4.76 (608/12,783) 0.28
In-hospital 1.14 (14/1,234) 0.88 (122/13,913) 0.34
Out-of-hospital 4.45 (51/1,147) 3.89 (497/12,767) 0.34
Target vessel revascularization 2.57 (29/1,127) 2.31 (291/12,602) 0.54
Major bleeding 1.42 (16/1,126) 0.99 (124/12,582) 0.11
Values are % (numbers) of observations; different denominators are due to missing data and deaths during follow-up; ARC = Academic
Research Consortium.
selection and a high compliance may explain the low
rates of MACE noted in our registry.
Despite the high compliance with DAPT, the rate of
ST was higher in the acute MI than in the no acute MI
group. Indeed, an ACS was a predictor of ST26 also
in the e-Cypher registry. The TRITON TIMI 38 study
randomly assigned 12,844 moderate to high risk ACS
patients scheduled for PCI to receive clopidogrel or
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Figure 1. Cumulative incidence of stent thromboses and major bleeding events up to 1 year in each study group.
prasugrel.27,28 The rates of ST increased depending
on the risk profile, reaching 2.8% in the STEMI group
treated with clopidogrel, after a median of 14.5 months.
No difference in rates of ST was noted between DES
and BMS recipients. The administration of prasugrel
lowered the rate of ST by 21%. Therefore, ST is a con-
cern in all acute MI patients undergoing primary PCI,
regardless of stent type. The causes of ST in the setting
of acute MI are multi-factorial. Clinical evidence for
a relationship between underlying vascular inflamma-
tion and ST has been found in patients with ruptured
plaque. Risk of ST is directly related to the acuity of the
index clinical syndrome preceding stenting. Patients
presenting with an ACS have a several-fold increased
risk for ST regardless of stent type compared with pa-
tients with stable symptoms.29,30 Possible histopatho-
logic mechanisms include the thin fibrous cap that
characterizes vulnerable plaque, abundant inflamma-
tory cells, and a necrotic lipid core.31 Implantation
of undersized stents has been recognized as a cause
of ST. In acute MI, vasoconstriction and underlying
thrombus may lead to underestimation of the reference
vessel size and positioning of an under-sized stent.32,33
Despite the use of thromboaspiration, residual throm-
bosis between the struts and the vessel wall has been
demonstrated and could potentially be a cause of early
ST.34 Of interest, the rate of late thrombosis, which
was the main concern for the use of DES in acute MI
was low in both groups.
Limitations of the Study. The source data were
verified in a random sample representing 20% of the
patients enrolled in e-SELECT. While this compares
favorably with other recent stent registries,26,35,36 the
underreporting of adverse events remains a potential
limitation. However, the monitored sample confirmed
that the data collection was reliable. Moreover, the
1.5% rate of definite ST at 1 year among our patients
presenting with acute MI was close to the 2.0% re-
ported by the fully monitored randomized TYPHOON
trial that used the same DES.4Another limitation is
the fact that patients enrolled were evidently selected,
since they were included in the registry only after hav-
ing undergone successful implantation of a SES, and
had no contraindication to prolonged DAPT. Finally,
the CYPHER Select R© or CYPHER Select R© Plus SES
stents will no longer be available for use after 2012.
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Table 5. Predictors of Adverse Events for Patients with Acute
MI Multiple Variable Regression Analysis at 360 Days
Hazard Ratio




13.4 [5.0, 36.0] <0.001
History of coronary artery
bypass graft surgery




58.9 [26.9, 129.1] <0.001
History of coronary artery
bypass graft surgery




1.3 [1.1, 1.6] <0.001
Total or partial temporary
interruption of DAPT
within 1st 30 days
10.1 [2.2, 46.9] 0.003
History of coronary artery
bypass graft surgery




2.6 [0.9, 7.9] 0.08
Female gender 2.5 [0.9, 7.1] 0.08
CI = confidence interval; DAPT = dual antiplatelet therapy.
Conclusions
In selected patients presenting within <24 hours of
acute MI onset and highly compliant with DAPT, the
implantation of SES was associated with low MACE
rates, similar to those observed in more stable patients.
The rate of ST was higher in patients presenting with
than without acute MI.
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